X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia
X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $34.17
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Top 3 Health Care Stocks That May Rocket Higher In April
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
X4 Pharmaceuticals Announces Reverse Stock Split
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia